Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adzenys ER
- Development stage
- Unknown
- Lead developer
- Aytu BioPharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Adzenys ER is a once-daily, extended-release liquid formulation of mixed amphetamine salts developed by Neos Therapeutics for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 years and older.[7][9] It uses Neos’ extended-release technology to provide a stable oral suspension of amphetamine that does not require refrigeration and is designed to deliver prolonged stimulant exposure over the day, enabling once-daily dosing similar in pharmacologic effect to other amphetamine-based ADHD therapies.[7] As a central nervous system stimulant, Adzenys ER increases synaptic concentrations of norepinephrine and dopamine in the brain by promoting their release and blocking reuptake, thereby improving attention and reducing hyperactivity and impulsivity in individuals with ADHD.[9]
- Brand names
- Adzenys ER
- Other names
- amphetamine extended-release oral suspensionamphetamine ER oral suspension
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on Adzenys ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adzenys ER.